tukysa
seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - antineoplastic agents - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.
tukysa 150 mg
merck sharp & dohme (israel-1996) ltd - tucatinib - film coated tablets - tucatinib 150 mg - tucatinib - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2-positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-her2 treatment regimens.
tukysa 50 mg
merck sharp & dohme (israel-1996) ltd - tucatinib - film coated tablets - tucatinib 50 mg - tucatinib - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2-positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-her2 treatment regimens.
itraconazole 10mg/ml oral solution
athlone pharmaceuticals limited - itraconazole - oral solution - triazole derivatives; itraconazole
sporanox 100 milligram capsule
ltt pharma limited - itraconazole - capsule - 100 milligram - itraconazole
sporanox 100mg capsules
imbat limited - itraconazole - capsule, hard - 100 milligram(s) - triazole derivatives; itraconazole
sporanox capsule
janssen inc - itraconazole - capsule - 100mg - itraconazole 100mg - azoles
sporanox solution
janssen inc - itraconazole - solution - 10mg - itraconazole 10mg - azoles
sporanox 100 mg capsules
lexon (uk) ltd - itraconazole - capsule - 100 milligram(s) - triazole derivatives; itraconazole
jamp itraconazole oral solution
jamp pharma corporation - itraconazole - solution - 10mg - itraconazole 10mg - azoles